Curocell

Curocell Acquisitions (Net)

The Acquisitions (Net) of Curocell (372320.KQ) as of Oct 28, 2026 is 23.23 B KRW. In the previous year, Acquisitions (Net) was 523.67 M KRW — a change of 4,336.03% (higher).

Acquisitions (Net)

23.23 BKRW

YoY

4,336.03%

Last updated:

Acquisitions (Net) of Curocell is 2024 23.23 B KRW. Acquisitions (Net) of Curocell was 2023 523.67 M KRW. It decreases by 4,336.03% higher compared to the previous year.

The Curocell Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2021
17.79 B KRW
Jan 1, 2022
-12.85 B KRW
Jan 1, 2023
523.67 M KRW
Jan 1, 2024
23.23 B KRW
The Curocell Acquisitions (Net) history
YEARAcquisitions (Net)YoY
23.23 BKRW+4,336.03%
523.67 MKRW-104.07%
-12.85 BKRW-172.22%
17.79 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Acquisitions (Net) of Curocell is 23.23 B KRW in 2024.

Acquisitions (Net) of Curocell changed from 523.67 M KRW to 23.23 B KRW, representing a 4,336.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Curocell since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Curocell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curocell

All Key Metrics — Curocell